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Abstract 
Background: DNA methylation plays a vital role in the cell, but loss‑of‑function mutations of the maintenance meth‑
yltransferase DNMT1 in normal human cells are lethal, precluding target identification, and existing hypomorphic lines 
are tumour cells. We generated instead a hypomorphic series in normal hTERT‑immortalised fibroblasts using stably 
integrated short hairpin RNA.
Results: Approximately two‑thirds of sites showed demethylation as expected, with one‑third showing hypermeth‑
ylation, and targets were shared between the three independently derived lines. Enrichment analysis indicated sig‑
nificant losses at promoters and gene bodies with four gene classes most affected: (1) protocadherins, which are key 
to neural cell identity; (2) genes involved in fat homoeostasis/body mass determination; (3) olfactory receptors and 
(4) cancer/testis antigen (CTA) genes. Overall effects on transcription were relatively small in these fibroblasts, but CTA 
genes showed robust derepression. Comparison with siRNA‑treated cells indicated that shRNA lines show substantial 
remethylation over time. Regions showing persistent hypomethylation in the shRNA lines were associated with poly‑
comb repression and were derepressed on addition of an EZH2 inhibitor. Persistent hypermethylation in shRNA lines 
was, in contrast, associated with poised promoters.
Conclusions: We have assessed for the first time the effects of chronic depletion of DNMT1 in an untransformed, dif‑
ferentiated human cell type. Our results suggest polycomb marking blocks remethylation and indicate the sensitivity 
of key neural, adipose and cancer‑associated genes to loss of maintenance methylation activity.
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Background
DNA methylation is an important mechanism for epige-
netic regulation of genes in both mouse and human [1]. It 
occurs mainly at the CpG dinucleotide, and methylation 
at this symmetrical site is efficiently maintained during 
replication by the action of the DNA methyltransferase 
1 (DNMT1) enzyme [2]. Methylation is known to play 
an important role in regulating imprinted loci [3], genes 
on the inactive X chromosome [4] and germline-specific 
genes [5] in mouse.
Where methylation occurs at the promoter of a gene, it 
is strongly associated with the silencing of transcription, 
particularly if there is a high density of CpGs, a so-called 
CpG island (CGI). However, studies have shown that 
most CGI are intrinsically protected from methylation [6, 
7] and only a small number shows dynamic changes dur-
ing development, mostly in the three classes mentioned 
above [5, 8], though there may be others which have not 
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yet been clearly defined. As you move outward from an 
island, the shores and shelves show higher levels of meth-
ylation and greater dynamic response [9], though here the 
link to changes in gene activity is less clear [10]. Methyla-
tion is also associated with larger regions of inert chro-
matin, such as the inactive X, pericentromeric repeats 
and regions rich in transposable elements [1], generally 
consistent with a repressive role. Recent genome-wide 
surveys have also indicated that high levels of methyla-
tion are found in the bodies of active genes, where they 
may facilitate transcription [11, 12]. In keeping with this, 
we and others recently showed that artificially decreasing 
intragenic methylation levels reduced steady-state tran-
script levels, consistent with a positive role for methyla-
tion in the gene body [11–13].
Another major system for epigenetic repression is via 
histone modification, particularly by the polycomb group 
of proteins, with EZH2 being one of the main enzymes 
involved [14]. A number of studies suggest an interplay 
between polycomb- and DNMT-mediated repression, 
with a generally negative correlation between DNA meth-
ylation and the H3K27me3 mark deposited by EZH2 [15, 
16]. Supporting this, a loss of DNA methylation caused 
a reshaping of the histone landscape and derepression of 
some polycomb targets in mouse ES cells [17], suggesting 
that DNA methylation helps to determine where poly-
comb marks are deposited.
While DNMT1 is the main maintenance methyltrans-
ferase, there also appears to be an important role for the 
de novo enzymes DNMT3A and DNMT3B in comple-
menting that activity at some loci [18, 19]. In order to 
clarify which genes are most sensitive to DNMT1 loss 
in human, a number of studies have been carried out 
using mutations within the gene to assess the effects of 
loss of methylation [19–22]. While this has been a fruitful 
approach in mouse embryonic stem (ES) cells, where null 
mutants are tolerated, differentiation of the mouse cells 
leads to cell death [20, 22, 23], whereas DNMT1 disrup-
tion in human ES cells is not tolerated even in undifferen-
tiated cells [24]. Genetic ablation in adult differentiated 
cells also leads to cell death within a few cell cycles, 
before passive demethylation of the genome can occur 
[23, 25]. One of the best-studied systems in humans con-
sists of HCT116 colon cancer cells carrying a hypomor-
phic allele in the DNMT1 gene together with a DNMT3B 
knockout (HCT116 DKO cells) [26–28]. Blattler et  al. 
[29] found that there was widespread and relatively uni-
form demethylation across the genome in the DKO cells, 
with small effects at CGI (most of which are normally 
unmethylated anyway) and relatively few genes showing 
derepression. There was no enrichment by gene ontol-
ogy (GO) analysis, but some effect at enhancers: how-
ever, this is complicated by the presence of the DNMT3B 
knockout alleles. Acute depletion of DNMT1 using an 
siRNA-mediated approach in embryonal carcinoma cells 
also found regions of low CpG density (open sea, shelf ) to 
be the most affected by loss of methylation [70]. Among 
the small number of dysregulated genes, there was some 
enrichment for cell morphogenesis and phosphorylation 
pathways.
Neither of these cancer cell lines, however, are a good 
model for the normal differentiated cell as they are trans-
formed, aneuploid, hypermethylated, and contain a 
number of different mutations in key regulatory genes. 
Additionally, acute depletion of DNMT1 results in cell 
cycle delay, triggering of the DNA damage response and 
increased rates of cell death [24, 25, 30], making it diffi-
cult to separate acute and chronic effects.
To circumvent some of the difficulties outlined above, 
we generated a series of isogenic human cell lines derived 
from the hTERT-immortalised normal fibroblast line 
hTERT1604 as previously described [30]. These are nor-
mosomic and non-transformed, and by using a stably 
incorporated plasmid with an shRNA targeting DNMT1 
we were able to isolate a number of clonally derived lines 
to allow identification of any cell line-specific effects. 
While these showed initially the range of shared features 
indicative of a global response to the loss of this criti-
cal regulator, including cell cycle delay, demethylation 
of imprinted genes and others, they could be cultured 
for longer under selection [30], allowing identification 
of loci with particular sensitivity for decreased main-
tenance methyltransferase activity. Here we set out to 
completely characterise the methylation changes seen in 
the cell lines using the Illumina Infinium HumanMeth-
ylation450 BeadChip (450k) array platform [31] and sub-
sequent analysis using the RnBeads pipeline [32]. These 
approaches were chosen due to their high reproducibil-
ity and low inter-operator variability, ensuring the reli-
able and sensitive detection of alterations in methylation. 
A sample of the observations was then further verified 
using locus-specific assays. In addition and for the same 
reasons, we used the HT-12 Expression v4 BeadChip 
array, to assay changes in transcription in our cell lines.
Methods
Cell culture
The parental or wild-type (WT) adherent hTERT1604 
lung fibroblast cell line [33] was cultured in 4.5  g/l glu-
cose DMEM (Thermofisher, Loughborough, UK) sup-
plemented with 10% FBS and 2× NEAA (Gibco/
Thermofisher). Generation of the hTERT1604 cell lines 
stably depleted of DNMT1 using a pSilencer construct 
(Thermofisher) has been previously described [30]. 
Knockdown (KD) cells were maintained as for WT, but 
medium was supplemented with 150 μg/ml hygromycin 
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B (Invitrogen/Thermofisher, Paisley, UK), which was 
removed at least 48 h before any experimental procedure. 
Treatment of cells with siRNA for 24 h was as previously 
described [34]: for the pulse-chase experiment cells were 
afterwards allowed to recover in normal media and pas-
saged as required for up to 36  days. The siRNA (Dhar-
macon ON-TARGETplus SMARTpool) for DNMT1 and 
DNMT3B, as well as scrambled control, was obtained 
from Invitrogen/Thermofisher. HCT116 and double 
knockout (DKO) cells [27] were cultured in 1 g/l glucose 
DMEM (Gibco) supplemented with 10% FBS and 1× 
NEAA (Gibco). DZNeP (Sigma-Aldrich, Dorset, UK) was 
used at a final concentration of 1 μM.
DNA extraction and bisulphite conversion
Genomic DNA was harvested from cells in log phase of 
growth. Samples were incubated overnight at 55  °C in 
lysis buffer [50 mM Tris pH 8, 0.1 M EDTA (both Sigma-
Aldrich), 0.5% SDS, 0.2  mg/ml proteinase K (Roche, 
West Sussex, UK)], with rotation, and DNA was subse-
quently isolated using the standard phenol/chloroform/
isoamyl alcohol (25:24:1 pH8, Sigma-Aldrich) extraction 
method. DNA quality was verified using gel electropho-
resis and UV absorbance measurements at 260/280 and 
260/230  nm using a Nanodrop UV spectrophotometer 
(Labtech International, Ringmer, UK). Bisulphite conver-
sion of 500 ng of DNA was carried out using the EpiTect 
bisulphite kit (Qiagen, Crawley, UK) according to the 
manufacturer’s instructions.
Hybridisation to 450K array and bioinformatic analyses
Three samples from each cell line were used to pre-
pare DNA, with at least one biological repeat in each 
set. DNA was assessed for purity and integrity as above 
prior to quantification using the Quant-iT PicoGreen 
dsDNA assay kit (Thermo Fisher Scientific) as per man-
ufacturer’s instructions. In total, 500  ng of high-quality 
bisulphite-converted (Zymo Research) DNA was checked 
for purity and fragmentation on a bioanalyser and then 
loaded on the Infinium HumanMethylation450 BeadChip 
[31] and imaged using an Illumina iScan (Cambridge 
Genomic Services). Output files in IDAT format were 
processed using the RnBeads [32] methylation analysis 
package (v1.0.0) which carries out all the analysis from 
import to differential methylation within the R platform 
(3.2.0). Briefly, quality control used the built-in probes 
on the array and included filtering out of probes contain-
ing SNPs, and checking for hybridisation performance. 
Normalisation was then carried out using the SWAN 
method in minfi [35] after background subtraction with 
methylumi.noob. The exploratory analysis module was 
used to generate probe density distributions and scatter 
graphs. The differential methylation analyses was based 
on a combined ranking score, which combined absolute 
effect size, relative effect sizes and p-values from statisti-
cal modelling into one score where rank is computed as 
the most conservative value among mean difference in 
means, mean in quotients and combined p value across 
sites in the region: the enrichment analysis used the com-
bined rank among the 1000 best-ranking regions and a 
hypergeometric test to identify GO terms in the AmiGO 
2 database [36]. Pairwise comparison of triplicate samples 
from each cell line against WT hTERT was also made to 
determine change in beta value and associated combined 
p-value, adjusted for multiple comparison using false dis-
covery rate (FDR). Some tailored analyses were also car-
ried out using custom scripts in R. Additional GO studies 
were performed using DAVID (v6.7) [37].
We used the GALAXY platform [38] to map sites 
showing highly reproducible changes (FDR < 0.05) against 
the locations of RefSeq genes or ChromHMM regions 
on the UCSC genome browser [39] for each cell line. GO 
category genes which showed changes in methylation at 
multiple sites in more than one KD cell line were scored 
as true hits (Yes in the FDR column), while GO catego-
ries with few or no sites reproducibly altered across rep-
licates (FDR > 0.05) or where methylation changes were 
small (< 0.1 β), inconsistent in direction, or not found in 
more than one KD cell line, were scored as false positives. 
Absolute β levels were used to measure median methyla-
tion across genes of interest using custom workflows in 
GALAXY, with further statistical analyses in Statistical 
Package for the Social Sciences software (SPSS) version 
22.0 (SPSS UK Ltd).
Locus‑specific methylation analysis
Amplification was carried out using the PyroMark PCR 
kit (Qiagen) with 2 μl bisulphite-converted DNA, 12.5 μl 
MasterMix, 2.5  μl CoralLoad Concentrate, 1.25  μl each 
primer (10  μM) and 5.5  μl nuclease-free  H2o using the 
following conditions: 15  min at 95  °C followed by 45 
cycles of 94 °C for 30 s, 56 °C for 30 s, 72 °C for 30 s and a 
final elongation step of 72 °C for 10 min. Pyrosequencing 
was carried out on the PyroMark Q24 System, accord-
ing to the manufacturer’s instructions (Qiagen). Most 
assays were designed in-house using the PyroMark Assay 
Design software 2.0 (LEP, MAGEA12, OR10J5, OR51E2, 
OR2AG1, PCDHA2, PCDHC4, UGT1A1, UGT1A4) prior 
to synthesis (Metabion, Germany): see Additional file 1: 
Table S1 for details: DAZL, SYCP3, D4Z4 and NBL2 
were as described [34, 40]. In some cases, pre-designed 
pyrosequencing primers were obtained from Qiagen 
(GABRQ PM00133483, GHSR PM00014350, SNRPN 
PM00168252). Clonal analysis was carried out as previ-
ously described [30].
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Hybridisation to HT‑12 microarray and bioinformatic 
analyses
Total RNA was extracted using the RNeasy minikit 
(Qiagen) as per manufacturer’s instructions, including a 
DNase step. RNA integrity was verified via gel electro-
phoresis, and quality and quantity were verified using a 
SpectroStar (BMG Labtech, Aylesbury, UK) and a bioana-
lyser (Agilent Technologies, Cheadle, UK). Two hundred 
nanograms of total RNA underwent linear amplification 
using the Illumina TotalPrep RNA Amplification Kit 
(Life Technologies/Thermofisher, Paisley, UK) follow-
ing the manufacturer’s instructions. Microarray experi-
ments were performed at Cambridge Genomic Services, 
University of Cambridge, using the HumanHT-12 v4 
Expression BeadChip (Illumina, Chesterford, UK). After 
scanning the data were loaded in GenomeStudio (Illu-
mina) and then processed in R (version 3.2.2). The data 
were filtered to remove any non-expressed probes using 
the detection p-value from Illumina, transformed using 
the variance stabilization transformation (VST) from 
lumi and normalised using the quantile method. Com-
parisons were made using the limma package with results 
corrected for multiple testing using false discovery rate 
(FDR) testing.
RNA and protein analysis
Transcriptional assays at individual loci using RT- and 
RT-qPCR were carried out essentially as in [34]: primer 
sequences are listed in Additional file  1: Table S1. Pro-
tein was extracted from cells growing in log phase 
using protein extraction buffer (50  mM Tris–HCl, 
150 mM NaCl, 1% Triton-X, 10% glycerol, 5 mM EDTA; 
all Sigma-Aldrich) and 0.5  µl protease inhibitor mix 
(Sigma-Aldrich). For Western blotting, 30  μg protein 
was denatured in the presence of 5  μl 4× LDS sample 
buffer (Invitrogen) and 2 μl 10× reducing agent (Invitro-
gen) in a total volume of 20 μl nuclease-free water (Qia-
gen) via incubation at 70 °C. Proteins were separated by 
SDS-PAGE and then electroblotted onto a nitrocellulose 
membrane (Invitrogen) and blocked in 5% non-fat milk 
for 1 h at room temperature (RT). Membranes were incu-
bated with anti-DNMT1 (a kind gift from Guoliang Xu) 
and anti-β-actin (Abcam ab8226) overnight at 4  °C, fol-
lowed by HRP-conjugated secondary antibody incuba-
tion at RT using ECL (Invitrogen).
Statistical analysis
Statistical analysis was performed by the RnBeads pack-
age, or separately in Excel (Microsoft Office Professional 
Plus 2013), Prism (Graphpad) or SPSS (v22.0). Experi-
ments were carried out in triplicate and included at least 
one biological replicate. PCR results were analysed using 
Student’s paired t-test. Pyrosequencing results were ana-
lysed by ANOVA within representative runs and using 
Student’s t-test on the average of multiple runs. Error 
bars on all graphs show standard error of the mean 
(SEM) or in the case of HT12 array data, 95% confi-
dence interval (CI), unless otherwise stated. Asterisks are 
used to represent probability scores as follows: *p < 0.05; 
**p < 0.01; ***p < 0.005 or n.s. not significant.
Results
Generation of isogenic hTERT1604 fibroblast cell lines
Isogenic lines carrying an shRNA construct targeting 
DNMT1 were generated by transfecting the hTERT-
immortalised human lung fibroblast cell line hTERT-
1604 with pSilencer plasmid containing an shRNA 
(Fig.  1a). The generation and initial characterisation of 
these isogenic cell lines have been previously described 
[30]. Here we took two sublines typical of the intermedi-
ate levels of knockdown (KD) seen (d8 and d10) as well 
as one line (d16) with relatively low levels of mRNA, with 
good agreement between reverse transcription quanti-
tative PCR (qPCR) and array results (Fig. 1b; all p < 0.05 
except d8 array). We also confirmed knockdown at the 
protein level using Western blotting, with HCT116 cells 
mutated in DNMT1 and DNMT3B [27] as controls 
(Additional file 3: Fig. S2A).
(See figure on next page.) 
Fig. 1 Cell line generation and overall changes seen in methylation levels. a Experimental approach: WT hTERT1604 fibroblasts were transfected 
with shRNA‑containing plasmid and grown in selective medium; colonies of resistant cells were expanded, and three (d8, d10, d16) showing 
reduced DNMT1 levels were then analysed using genome‑wide methylation and transcription arrays on the Illumina platform. b Levels of DNMT1 
mRNA in cell lines from array and qPCR: error bars represent 95% confidence intervals around median, and standard error of the mean (SEM), 
respectively. All three knockdown (KD) lines were significantly depleted at p < 0.05 for both assays (except d8 array). c Overall methylation levels in 
WT and KD cells as measured by 450K: a β value of 1 equates to 100% methylation. Median values are indicated by the line, and whiskers represent 
interquartile range. The positions of the medians are also indicated at right (arrowheads). d The difference in median β value between each KD cell 
line and WT is shown first for all sites assayed (see c above) and then for each type of genomic element. CGI, CpG island; shore, region adjacent to 
CGI; shelf, adjacent to shore; sea, all other. See also Additional file 3: Fig. S2B. e Probe density distributions; in KD there is a decrease in the number of 
fully methylated sites (β closer to 1) and an increase in the number of unmethylated sites (β closer to 0), as well as in probes showing intermediate 
levels of methylation (arrow). f Numbers of sites (×104) showing significant changes in methylation (FDR < 0.05) compared to WT: the set of com‑
mon sites is largest in each case, with close to twice as many sites commonly losing methylation in comparison with those gaining
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Characterisation of overall changes in absolute 
methylation levels in depleted lines
Using the 450K array [31] and processing in RnBeads [32] 
to assess methylation levels across the genome (Fig. 1c), 
there was still a wide range of methylation values (given 
for the array as a value β ranging from 0 to 1) in KD 
lines as compared to WT, but the median values were 
decreased as expected in all three with d8 being compa-
rable to d10, while d16 was lower (arrowheads at right). 
Principle components analysis and examination of the 
sites showing greatest differences in methylation between 
the stable lines confirmed that d8 and d10 were most 
similar (Additional file  2: Fig. S1). Probes on the array 
were annotated by location relative to genomic features, 
and while all regions showed a decrease in methylation, 
the difference in median values was smallest for CGI, 
which were unmethylated anyway in parental cells (β < 0.1 
in WT), while the separation in medians was greatest at 
shelves and shores, where methylation levels were higher 
(Additional file 3: Fig. S2B). This can most clearly be seen 
by plotting the difference in medians (Fig. 1d). Both WT 
and the KD cell lines showed the typical bimodal probe 
density distribution pattern reported in most cell types 
[31] (Fig. 1e). Overall, there was an increase in the num-
bers of less methylated probes (β < 0.25) in the KD cell 
lines and a decrease in the numbers of highly methyl-
ated probes (β > 0.65). For individual regions CGI again 
showed the smallest change, while gene bodies (genes) 
appeared most altered (Additional file 3: Fig. S2C).
To determine whether methylation was lost stochasti-
cally in each KD cell line given the variation seen (Addi-
tional file 2: Fig. S1), or was more targeted, we determined 
the degree to which affected sites were shared between 
the three cell lines (Fig.  1f ). The largest set of sites los-
ing methylation (17.2 × 104) was that shared between all 
three KD lines, supporting a non-random loss. A spike in 
numbers of probes showing intermediate levels of meth-
ylation (β ~ 0.50) in KD cell lines in the density profile 
plot (Fig. 1e, arrow) had indicated that a possible gain in 
methylation might also be occurring at some sites. Analy-
sis showed that a substantial number (9.1 × 104) of sites 
gaining methylation are shared between all three KD 
lines, indicating reproducible gains in methylation at par-
ticular CpGs.
Overall pattern of sites showing significant differential 
methylation on DNMT1 depletion
We compared WT cells to all three KD lines using the 
RnBeads package in R and combined rank scoring (see 
methods). This confirmed that d16 has the greatest num-
ber of demethylated sites using a false discovery rate 
(FDR) cut-off of p < 0.05, but at p < 0.001 all three lines 
have comparable numbers of hypo- and hypermethylated 
sites (Additional file 4: Fig. S3A), with more sites losing 
than gaining. An analysis of the 1000 best-ranking sites 
highlights sites common to all three KD lines (Additional 
file 4: Fig. S3B), confirming that there are large numbers 
of sites which respond in the same way in each KD, with 
an excess of probes showing loss over gain.
We then looked to see whether shared probes were 
enriched in any particular gene region. As we were inter-
ested in changes which might cause altered transcrip-
tion, we focussed on CGI, promoters and gene bodies 
(hereafter genes) rather than shores, shelves or open sea, 
where correlations with transcriptional output are harder 
to assess. Using a hypergeometric test in RnBeads, both 
promoters and genes, but not CGI, showed significant 
enrichment in demethylated probes for particular gene 
ontology (GO) terms. Table 1 indicates the top 3 ontol-
ogy classes under biological process (BP) and molecular 
function (MF). For loss of methylation, examining com-
mon genes and processes suggested that three classes of 
genes were common to the enriched GO terms, which 
we grouped as follows: (1) genes involved in neuroepi-
thelial differentiation; (2) genes involved in fat homoe-
ostasis/body mass (FBM); and (3) olfactory receptor 
genes (groups 1–3 in Table 1), all of which will be dealt 
with below. The only orphan GO term whose mem-
bers had multiple high-confidence demethylated sites 
was GO:0007506 gonadal mesoderm formation, which 
largely consists of members of the TSPY gene family on 
the Y chromosome. For gain of methylation, the same 
was true in that a relatively small number of histone 
modifier genes (group 4), represented under several GO 
terms, were responsible for many of the hits. In addi-
tion, the GO terms for glucuronosyltransferase activity 
(GO:0015020) and for regulation of megakaryocyte dif-
ferentiation were also represented (Table 1). These were 
then curated by looking for sites showing reproducible 
changes (FDR < 0.05) in all KD lines (described more fully 
in “Methods” section), which indicated strong support 
[Yes (Y) in confirm column, Table 1] for all GO categories 
showing loss, but only in two showing gain (GO:0015020 
and GO:0004984). We then set about verifying these 
targets.
Loss of methylation at the protocadherin gamma gene 
cluster particularly affects the A and B class variable genes
A main contributor to the enrichment of neuroepithelial 
genes are the protocadherin genes. Protocadherin α, β 
and γ (PCDHA, PCDHB and PCDHG) genes are located 
in three linked clusters on chromosome 5 and give rise to 
neural cell–cell adhesion proteins, with significant loss of 
methylation across the whole region in all three cell lines 
(Additional file 4: Fig. S3C). The α and γ proteins have a 
variable extra-cellular recognition domain, either A, B 
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or C-type, attached to a constant transmembrane and 
intracellular domain. This is achieved at the gene level by 
alternative 5′ exons encoding the variable region being 
spliced to the constant region exons. Figure  2a shows 
the tracks containing sites with significant (FDR < 0.05) 
methylation differences between KD and WT cells for the 
PCDHG cluster. These reveal loss of methylation (in red 
in Fig. 2a) at most A and B class variable exons in all three 
KD cell lines, but not at the C class variable or the con-
stant exons. Array probes were present in this region, and 
examination of the absolute rather than relative methyla-
tion (amber, top track in Fig.  2a) confirmed high levels 
of methylation in WT, where median β values were high 
for all variable exons (Fig.  2b). Methylation decreased 
in all three KD lines, with d10 showing the least effect 
(Fig.  2b). Methylation was substantially altered at all A 
and B class variable exons, but not at the C class (Fig. 2c). 
We could experimentally verify the loss of methylation at 
A2 (Fig. 2d), and no change at C4 (Fig. 2e), using pyrose-
quencing assays (pyroassay).
Some demethylation of other neuroepithelial genes in 
this GO category was also seen from the array, such as 
S100P, ROBO1 and PAX6, with significant (p < 0.05) dem-
ethylation of S100P in two-thirds of KD cell lines con-
firmed by pyrosequencing (not shown).
Loss of methylation at other targets including fat 
homoeostasis/body mass (FBM) genes
Another class of genes showing enrichment all appear 
to be involved in some aspect of triglyceride processing, 
Table 1 Gene ontology analysis for differentially methylated sites
BP biological process, MF molecular function, GO FID gene ontology family identification code, P probability value, OR odds ratio, Ex expected number of hits, Obs 
observed number, Total total number of genes in that family, Grp-see below; confirm Y/N, confirmation given by FDR tracks Yes/No
Groups (Grp): 1 = neuroepithelium; 2 = Fat homoeostasis/body mass (FBM); 3 = olfactory receptor; 4 = histone modifier
Type GO FID P OR Ex Obs Total GO Term Grp confirm
Loss
Promoter
 BP 0098609 0.0011 3.0454 4.2148 12 189 Cell–cell adhesion 1 Y
0007156 0.0011 3.4722 3.0998 10 139 Homophilic cell adhesion via plasma membrane 1 Y
0010982 0.0015 88.2036 0.0669 2 3 Regulation of high‑density lipoprotein particle clearance 2 Y
 MF 0004888 0.0001 1.9709 24.2681 44 1055 Transmembrane signalling receptor activity 3 Y
0005509 0.0001 2.2488 14.3768 30 625 Calcium ion binding 1 Y
0004871 0.0003 1.7441 33.6302 54 1462 Signal transducer activity 3 Y
Gene
 BP 0007506 0 130.3775 0.1339 5 7 Gonadal mesoderm development Y
0032375 0.0001 25.9783 0.2295 4 12 Negative regulation of cholesterol transport 2 Y
0045409 0.0001 77.705 0.0956 3 5 Negative regulation of interleukin‑6 biosynthetic process 2 Y
 MF 0008083 0.0009 3.5742 3.0015 10 158 Growth factor activity 3 Y
0004984 0.0014 2.5939 6.136 15 323 Olfactory receptor activity 3 Y
0038023 0.0014 1.7776 22.9102 38 1206 Signalling receptor activity 3 Y
Gain
Promoter
 BP 0035574 0 443.1106 0.4729 14 15 Histone H4‑K20 demethylation 4 N
0045653 0 147.6833 0.5359 14 17 Negative regulation of megakaryocyte differentiation N
0016577 0 26.4022 1.0404 15 33 Histone demethylation 4 N
 MF 0035575 0 452.3692 0.4637 14 15 Histone demethylase activity (H4‑K20 specific) 4 N
0032451 0 21.0879 1.1747 15 38 Demethylase activity 4 N
0015020 0 10.1109 0.8965 7 29 Glucuronosyltransferase activity Y
Gene
 BP 0035574 0 280.0725 0.4039 14 16 Histone H4‑K20 demethylation 4 N
0045653 0 140.0181 0.4544 14 18 Negative regulation of megakaryocyte differentiation N
0006335 0 31.0869 0.8078 14 32 DNA replication‑dependent nucleosome assembly 4 N
 MF 0035575 0 287.2955 0.3942 14 16 Histone demethylase activity (H4‑K20 specific) 4 N
0032451 0 24.654 0.9856 15 40 Demethylase activity 4 N
0004984 0 4.4768 7.9586 31 323 Olfactory receptor activity 3 Y
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energy homoeostasis and body weight regulation 
(Table  1), including leptin (LEP), ghrelin/growth hor-
mone secretagogue receptor (GHSR) and genes encoding 
the very low density lipoproteins APOC1, APOC2 and 
APOC3. Median levels of methylation in the gene bod-
ies were approximately 45% in WT (β = 0.45) and showed 
significant (p < 0.05) decreases in the KD lines (Fig.  3a). 
Most individual genes also showed substantial loss, with 
the exception of the ANXA genes (Fig. 3b). Loss of meth-
ylation at the LEP and GHSR promoters was confirmed 
using pyroassay (Fig. 3c).
Olfactory receptor (OR) genes appeared in a number 
of GO categories as having lost methylation, though 
some gains in the gene body were also indicated 
(Table 1). ORs encode G protein-coupled receptor pro-
teins and are members of a large gene family, many of 
which are grouped into major clusters, particularly 
on chromosome 11 [41]. To buffer against stochastic 
effects due to the large gene family involved, we car-
ried out a second analysis starting instead with sites in 
promoters showing reliable methylation loss compared 
to WT (FDR < 0.05) in the triplicates of each KD line 
Fig. 2 Loss of methylation at the protocadherin γ (PCDHG) cluster of neuroepithelial identity genes. a Structure of the PCDHG cluster showing the 
5′ variable exons (A, B and C classes) which are spliced to the 3′ constant exons (right). The top track (amber) shows absolute β values in the WT 
fibroblast cells from the 450K array, which range from 1(fully methylated) to zero (unmethylated). Only the sites showing significant differences 
from WT (FDR < 0.05) in each cell line are shown in the three tracks below, with decreases in red representing loss of methylation, and gains in blue. 
The size of the bar is proportional to the magnitude of change: maxima and minima are indicated on the scales at left. The locations of CpG islands 
(CGI) are also shown. Pyroassay locations are boxed. b Median β values for all variable exons. Significant differences (Mann–Whitney U) are indicated: 
*p < 0.05; **p < 0.1; n.s., not significant. c Methylation at each exon in WT and d16 cells obtained by taking the median of the absolute β value for all 
probes at that exon. The variable class C exons are underlined. d Average methylation values in WT and KD cells obtained from a pyrosequencing 
assay (pyroassay) designed to cover CpGs in the A2 exon. Bars represent SEM; ***p < 0.001, t‑test. e Methylation at the C4 variable exon by pyroassay, 
shown as a control
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and then overlapping these (Fig. 3d) to see which sites 
were common to all three KD cell lines (Additional 
file  5: Table S2). Ontology analysis of these common 
sites using DAVID independently highlighted signal-
ling receptor genes and more particularly olfactory 
receptors (n = 21). This group of OR genes also showed 
significant demethylation compared to WT (Kruskal–
Wallis, p < 0.05) across the genes when median meth-
ylation at all available probes was analysed (Additional 
file  4: Fig. S3D). We chose three of these genes—
OR10J5, OR51E2 and OR2AG1—located on different 
chromosomes and could verify loss of methylation in 
all KD lines (Fig. 3e).
The final GO category of genes (GOFMID:0007506) 
showing loss of methylation (Table 1) consists largely of 
the TSPY gene family (TSPY1-4, 8 and 10) located on 
the Y chromosome and thought to be implicated in both 
normal gonadal development and in gonadoblastoma 
[42]. These also showed clear evidence of demethylation 
(Fig. 3f ).
Gains in methylation affect the UGT1A locus
As indicated above, with respect to gains in methylation 
only two of the GO classes identified in the genome-wide 
screen (Table 1) contained multiple sites showing signifi-
cant gains in methylation (FDR < 0.05, > 0.1 gain in β). One 
of these was the olfactory genes, discussed above: the other 
GO term GO:0015020 was largely comprised of mem-
bers of the UGT1A family. This gene family has a similar 
structure to the PCDHG cluster, where unique alternate 
5′ exons splice to common 3′ exons, but in this case codes 
for a series of nine UDP-glucuronosyltransferase enzymes 
(UGTs). Substantial gains in methylation can be seen at 
the upstream promoters controlling the 5′ exons (Fig. 4a), 
most of which lack CGI. Median methylation levels also 
showed clear increases overall in the KD lines (Fig.  4b), 
though these did not reach significance. Most individual 
exons also showed a sharp increase (Fig. 4c), with A1 being 
a clear exception in all lines. We confirmed a significant 
gain in methylation in each cell line at A4 (Fig. 4d) but no 
alteration at A1 (Fig. 4e). In contrast to the clear gains in 
Fig. 3 Loss of methylation at fat homoeostasis/body mass (FBM) genes, olfactory receptors and the TSPY genes. a Median β values for all FBM 
genes (following curation) in WT and KD cell lines; significant differences (Mann–Whitney U) are indicated. b Median methylation values at each 
FBM gene in WT and d16 cells. c Average methylation levels obtained from pyroassays at the Leptin (LEP) and Ghrelin/growth factor receptor secre‑
tagogue (GSHR) promoters. d CpG located in promoters which showed highly reproducible loss of methylation (FDR < 0.05) were identified. The set 
of sites common to all three KD cell lines (n = 1185) was found to be enriched for olfactory receptors (such as the three indicated) using the DAVID 
tool. e Pyroassays designed for the three olfactory receptor genes from (d) confirmed methylation was consistently reduced across all KD cell lines. f 
Browser view showing loss of methylation (red) at the CGI‑containing promoters for members of the TSPY family on the Y chromosome
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all three lines for UGT1A, the histone modifier group also 
identified as gaining methylation (Table  1, group 4) con-
tained few FDR-supported sites and these often did not 
overlap between cell lines, with median β levels also not 
differing significantly (Additional file 4: Fig. S3E).
A cluster of loci showing gain of methylation on the X 
chromosome
Given that there were considerable numbers of probes 
showing gain in methylation, but few of the GO classes 
from the RnBeads analysis contained testable targets by 
our criteria, we tried an alternative analysis as for the 
OR above. Sites associated with promoters and which 
showed reliable (FDR < 0.05) gains were identified in each 
KD line, and then the lists of cognate genes were com-
pared to find those which were common to all three cell 
lines (Fig.  5a). Examination of the 201 promoters from 
this analysis (Additional file  5: Table S2) failed to show 
any significantly enriched terms in DAVID. However, sev-
eral of the genes showing the greatest gain in methylation 
were located on the X chromosome, including GABRQ 
and members of the MAGE family of cancer/testis anti-
gens such as MAGEA12. Mapping of FDR sites to the X 
chromosome showed that adjacent domains could vary 
in methylation level by more than 80% in either direction 
(Fig.  5b). Pyroassays for GABRQ and the neighbouring 
Fig. 4 Gains in methylation at the clustered UGT1A locus. a Structure of the UGT1A cluster showing the 5′ variable exons (UGT1A1–UGT1A10) which 
are spliced to the 3′ exons (right). Key to tracks as before; pyroassay locations (UGT1A1 and UGT1A4) are boxed. b Median β values for all first exons: 
though medians are higher in KD lines these failed to reach statistical significance. c Median absolute β values at individual first exons in WT and 
d16 cells. d Average methylation values in WT and KD cells obtained from a pyrosequencing assay (pyroassay) designed to cover CpGs in the A4 
exon. e Methylation by pyroassay at the A1 exon, shown as a control
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MAGEA12 gene confirmed significant gains in methyla-
tion at the GABRQ promoter and in the MAGEA12 gene 
body (Fig.  5c). Clonal analysis for GABRQ indicated a 
uniform increase in methylation (78 vs. 16%) across all 
adjacent CpG at this locus (Fig. 5d). Both direction and 
degree of change in methylation were highly correlated 
between pyrosequencing and the 450K array across all 
sites which were covered by both types of assay (r = 0.916 
for loss of methylation r = 0.818 for gain in methylation).
Transcriptional changes are enriched at cancer/testis 
antigen genes on X and Y
To see whether methylation changes were accompanied 
by large-scale changes in transcription, we carried out a 
genome-wide screen using the HT12 array which assays 
most RefSeq genes. Figure  7a shows the distribution of 
changes comparing d8 and WT: genes which showed > 2 
fold change (FC) and with scores of p < 0.05 are high-
lighted, with the greater spread to the right indicat-
ing a greater tendency to derepression. Relatively small 
numbers of genes were affected (Fig.  6b), particularly 
at higher stringency (FDR < 0.01), and d16 showed few-
est dysregulated genes. To determine common targets, 
we looked for shared genes (Fig. 6c). DAVID analysis on 
the genes common to all three (n = 70; Additional file 6: 
Table S3) indicated significant enrichment for genes cod-
ing for MAGE domains (Fig.  6d). MAGE genes on the 
X chromosome were previously identified as showing 
large changes in methylation (Fig. 5): also appearing here 
was a TSPY family member (Table 1, Fig. 3f ). Upregula-
tion of members of these gene classes could be verified 
by RT-PCR (Fig.  6e) and showed similar direction of 
change to the array, and greater magnitude, by RT-qPCR 
(Fig.  6f ). Consistent with the transcriptional upregula-
tion, median methylation levels at the promoters of these 
genes were lower than WT (Fig. 6g). Interestingly, there 
was an overall increase in intragenic (as opposed to pro-
moter) methylation in the larger group of transcription-
ally dysregulated genes common to d8 and d10 (n = 764, 
see Fig.  6h and Additional file  6: Table S3), which may 
Fig. 5 Gains in methylation on the X chromosome. a Sites reliably showing gain in methylation and located in promoters were analysed to identify 
those common to all three KD lines (n = 201). Some of these sites showing the greatest change in methylation were located on the X chromo‑
some including MAGEA12 and GABRQ. b Schematic showing the locations of the two genes adjacent to each other on X in a region showing gain 
in methylation. Tracks indicate the locations of all 450K probes and CGI; the positions of the pyroassays are also indicated; the scale bar pertains to 
the bottom part of the schematic; ∆β, change in beta value. c Methylation as determined by pyroassay at the two genes indicated in a, b. d Clonal 
analysis of GABRQ in WT and d8. Filled circles represent methylated sites, open circles unmethylated. The CpG which were also analysed by the 
pyroassay (pyro) and the 450K array (asterisk) are indicated
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Fig. 6 Transcriptional dysregulation of genes on the X and Y chromosomes correlates with methylation changes. a Volcano plot showing log fold 
change (FC) in transcription as measured by HT12 array versus FDR‑corrected significance values: genes with > 2FC and FDR < 0.05 are highlighted 
in red. b Numbers of dysregulated genes at different FDR thresholds for the different KD lines. c Genes common to more than one KD line at 
FDR < 0.05; total numbers in each cell line are indicated in brackets. d Ontology enrichment output from DAVID for the genes common to all KD 
lines. e RT‑PCR analysis of the three MAGE genes on X and a member of the TSPY gene family on Y highlighted in DAVID analysis (C). ACTB is a load‑
ing control; −ve, negative control lacking cDNA. A 100‑bp ladder is shown at left with the 200‑bp band indicated by an arrowhead. f Transcrip‑
tion levels of indicated MAGE genes from the HT12 array or by qPCR. Error bars are 95% CI for the array, SEM for qPCR; fold change was significant 
(p < 0.05) in all cases. g Median β values on 450K array for probes at MAGE promoters were decreased, though failed to reach significance. h Gene 
body methylation was increased in transcriptionally upregulated genes
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reflect increasing gene body methylation accompanying 
transcription.
Regions hypomethylated in shRNA lines correlate 
with polycomb repression
To investigate why losses in methylation occurred at the 
same positions in all KD lines, we used ENCODE data to 
look at chromosomal distribution, replication timing and 
chromatin features which might be important, since the 
DNMTs have no DNA sequence specificity themselves. 
Of these, the chromatin marks were most informative, 
in particular the ChromHMM dataset on lung fibro-
blasts which partitioned the genome into different types 
of chromatin based on a set of distinguishing histone 
marks and other features [43]. This indicated that probes 
significantly losing methylation in our shRNA lines are 
most densely distributed across regions which are nor-
mally polycomb-repressed or are heterochromatic/low-
signal regions in lung fibroblasts (Fig.  7a). Specifically, 
many regions show a striking correlation between poly-
comb marking and methylation loss, such as the LEP 
and neighbouring PRRT4 genes (Fig. 7b): in contrast, the 
intervening MGC27345 and RBM28 genes at that locus, 
which are highly methylated in WT cells (top track), 
show little or no loss of methylation and have chromatin 
marks associated with transcription.
These data suggested that polycomb-repressed regions 
might be more susceptible to demethylation than oth-
ers. To test whether these regions lost methylation more 
readily than others, we treated hTERT1604 with siRNA 
for 72  h, which led to acute depletion of the DNMT1 
mRNA (Fig.  7c). We found, however, that there was lit-
tle difference between polycomb-repressed and other 
regions in terms of demethylation in the siRNA-treated 
lines (Fig.  7d), in contrast to the shRNA lines where 
losses were concentrated at the former (Fig.  7d). This 
could also be seen at the LEP locus, where MGC27345 
and RBM28 now showed loss of methylation following 
siRNA treatment (Fig.  7b, siRNA track). Also of note, 
almost no probes showed gains in methylation relative to 
WT in the siRNA cells (Fig. 7e), indicating that this effect 
is associated exclusively with chronic treatment. These 
results suggested that gains of methylation had occurred 
only in shRNA lines and had effectively restored methyla-
tion to near WT levels at most regions outside of those 
marked as polycomb-repressed.
Since transcriptional analysis did not highlight dys-
regulation of polycomb regions in shRNA cells (Fig. 6d), 
we tested to see whether polycomb-mediated repression 
was being maintained there in the absence of DNA meth-
ylation. To do this, we treated with DZNep, an inhibitor 
of EZH2, and confirmed the upregulation of a positive 
control gene SLCA4 (Fig. 7f ) as previously reported [44]. 
Likewise, HOXC13—a known polycomb target—showed 
derepression (Fig.  7f ). The FBM genes marked by poly-
comb including LEP showed reactivation to a compara-
ble degree to SLCA4, whereas the MAGEA12 gene which 
is in a heterochromatic region not marked by polycomb 
showed little effect (Fig. 7f ).
To further investigate the difference between acute and 
chronic DNMT1 depletion in these cells, we first exam-
ined the effects of acute depletion by siRNA on the loci 
identified in the stable lines: this confirmed that loci 
such as the clustered protocadherins and the fat/body 
mass genes also lose methylation on short-term deple-
tion by siRNA (Fig. 7g). Following treatment, cells were 
then allowed to recover in the absence of siRNA for an 
extended period (36  days). DNMT1 levels returned to 
normal rapidly (Fig.  7h). Examination of the methyla-
tion response at various gene classes was very instructive. 
Germline genes (SYCP3, DAZL), which are known to 
become de novo methylated to high levels during somatic 
differentiation [5, 34], showed initial loss versus a scram-
bled control (Scr), followed by remethylation over time 
to near WT levels (Fig.  7i), confirming that the hTERT 
cells possess sufficient de novo activity to remethylate 
(See figure on previous page.) 
Fig. 7 Methylation loss is concentrated at regions normally repressed by polycomb. a Distribution of probes showing significant loss per chromatin 
state—numbers of probes are shown at left, chromatin states below: tcn, transcription; heterochrom/Lo, heterochromatin or low signal; repeti‑
tive, repeat DNA. b Region around the LEP gene: tracks as before, with the addition of data from cells treated with siRNA for 72 h (top). A track 
showing ChromHMM chromatin states from NHLF foetal lung fibroblasts is shown at bottom: grey, polycomb‑repressed; green, transcriptionally 
active (full colour key at top right). c DNMT1 mRNA levels by qPCR following treatment with siRNA (+) for 72 h compared with scrambled control 
(Scr). ACTB is shown as a control; ladder as above. d Median β values for all regions (WT) compared to medians for polycomb‑repressed regions 
(Polycomb), or all other regions (Other) in the cell lines indicated at top; remeth, remethylated. e Numbers of probes showing loss and gain in 
methylation in hTERT cells following treatment with siRNA for 72 h compared with the shRNA lines (averaged); #, number. f mRNA levels for the 
indicated genes in shRNA lines treated with the EzH2 inhibitor DZNeP; UNT, untreated; bars represent SEM, experiment carried out in duplicate. g 
Median β values for all variable exons at the PCDHG locus (left) and for fat/body mass genes (FBM, right): compare d16 shRNA lines with cells treated 
with siRNA. h DNMT1 mRNA levels in WT cells exposed to siRNA for 48 h, then allowed to recover in normal medium; comparisons were made to a 
scrambled siRNA negative control (Scr). i Methylation levels by pyroassay at the loci indicated during the transient KD and recovery shown in (h); 
timepoints are in days. All loci showed significant loss of methylation: LEP and SNRPN showed no significant gain versus lowest methylation level, 
while PCDHGA2 showed no significant gain between d22 and d36
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the genome, as already suggested (Fig. 7b–e). Imprinted 
genes are normally unable to regain methylation somati-
cally [45], and we could confirm that the SNRPN imprint 
control region failed to remethylate (Fig.  7i). The poly-
comb-marked genes LEP and PCDHGA2 were also 
refractory to de novo methylation, either showing no 
gain (LEP) or reaching a plateau at an intermediate level 
of recovery only (PCDHGA2) (Fig. 7i).
Gain in methylation is associated with poised promoters 
in shRNA lines
Having established that loss of methylation in shRNA 
lines is linked to polycomb repression, we wished to 
determine what features are associated with gains in 
methylation in these chronically depleted cell lines. As 
indicated, gains were not seen genome-wide following 
acute depletion using siRNA (Fig.  7e) and specific loci 
such as UGT1A showed instead loss of methylation on 
acute treatment (Fig.  8a, siRNA track), suggesting that 
hypermethylation is associated with longer-term culture 
of the shRNA-containing cell lines. To investigate what 
features might be associated with such loci, we looked 
to see which chromatin states in shRNA lines showed 
the highest median β for probes which gained methyla-
tion and the largest difference in methylation (Fig.  8b). 
This identified weak and poised promoter categories, and 
comparing shRNA lines to WT (Fig. 8c), the median val-
ues were more different for poised than for weak promot-
ers (0.4 vs. 0.2, Cohen’s D test). These results suggested 
that poised promoters attract de novo methylation par-
ticularly strongly. Consistent with this, hypermethylation 
in the shRNA lines is centred around the UGT1A pro-
moters and not the common 3′ exons (Fig. 8a). A hetero-
chromatic location may contribute to over-methylation, 
since genes in adjacent active chromatin show restora-
tion of normal methylation (Fig.  8a, compare siRNA to 
d10, d16 for DGKD), but not hypermethylation. While 
UGT1A transcription levels were very low compared to 
expressing cells by RT-qPCR (not shown), available HT12 
array data showed a consistent decrease in transcription 
in all three shRNA lines (Fig.  8d, left), correlated with 
gains in methylation at the cognate promoters (Fig.  8d, 
right).
Further analysis confirmed that while gains in meth-
ylation were seen across all the UGT1A exons in all 
shRNA lines (Fig. 8e), all of these exons showed a loss of 
methylation following acute depletion with siRNA. We 
took advantage of our transient depletion and recovery 
experiment (Fig.  7h, i) to examine levels of methylation 
at UGT1A4 using pyrosequencing: this showed that while 
the region indeed loses methylation on acute depletion, 
it undergoes steady de novo methylation following recov-
ery and at day 36 was the only gene examined whose 
methylation exceeded that seen in the scrambled control 
(32.4 vs. 31.3%), suggesting that these genes are indeed 
susceptible to hypermethylation.
One possible reason for the gains in methylation seen 
in the shRNA lines could be over-expression of a de novo 
enzyme. Previous reports have indicated that between 
them, DNMT3B and DNMT1 account for the major-
ity of methylation in cultured adult human cells and 
that there may be a role for DNMT3B in maintenance as 
well as de novo methylation [27]. We saw little change in 
DNMT3B levels in the DNMT1 KD lines from the HT12 
transcriptional array (Additional file 7: Fig. S4A) or RT-
PCR (not shown), indicating that gains in methylation 
are not due to DNMT3B over-expression. To investi-
gate a possible role in maintenance methylation, we car-
ried out a transient siRNA treatment and could achieve 
robust knockdown of DNMT3B in the cells (Additional 
file 7: Fig. S4B). While some germline genes showed little 
effect, loci previously shown to require DNMT3B includ-
ing D4Z4 and NBL2 did show loss of methylation (Addi-
tional file 7: Fig. S4C), confirming that we had achieved 
a functional depletion. Examination of the loci identified 
in our DNMT1 shRNA clones showed that these loci also 
showed loss of methylation in DNMT3B KD cells (Addi-
tional file 7: Fig. S4C), suggesting that loci which remain 
hypomethylated in the shRNA clones also require input 
from DNMT3B to retain WT methylation levels.
Discussion
Summary and model
We and others have previously shown that acute deple-
tion of DNMT1 using siRNA triggered the DNA dam-
age response and cell cycle perturbations in human 
cell lines, making it difficult to identify genes which are 
directly controlled by methylation. Here we used iso-
genic shRNA-containing derivatives of a normosomic 
lung fibroblast cell line to look at the effects of chronic 
depletion of the protein. We characterised the altera-
tions in methylation and transcription using microar-
rays in three different cell lines, processing them using a 
highly reproducible pipeline, and verified changes using 
locus-specific pyrosequencing or RT-qPCR assays. Addi-
tionally, we compared the effects on methylation of this 
chronic depletion to the effects of acute depletion using 
siRNA, as well as investigating possible contributions 
by DNMT3B. Finally, we investigated the correlations 
between chromatin state and DNA methylation and 
showed a role for polycomb-mediated repression at some 
of the loci.
Our results show that while both siRNA and shRNA-
treated cells lose methylation overall as would be 
expected, only the latter show gains in methylation, most 
likely reflecting selection against the deleterious effects 
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of hypomethylation during clonal expansion and cul-
ture. Figure 8e shows what we propose to have occurred: 
shRNA treatment gave initial widespread demethylation 
in all three clonal lines, since each line shows the pres-
ence of some highly demethylated sites distributed across 
the genome, but methylation seems to have recovered 
at most CpGs (Fig.  8e red line). Comparison to normal 
chromatin patterns in human lung fibroblasts indicated 
that remaining hypomethylation in the expanded cells 
was concentrated at regions normally marked for repres-
sion by polycomb (Fig. 8e purple line), while the smaller 
number of regions becoming hypermethylated relative to 
the parental cell line are associated with poised promot-
ers (green line). TET expression was not detected, and 
the cells had little or no 5-hydroxymethylation (5hmC; 
data not shown), in keeping with other reports [46], sug-
gesting that the hypermethylation does not represent 
5hmC. Likewise, no over-expression of DNMT3B was 
detected.
In terms of what type of gene was particularly affected 
by chronic DNMT1 KD, the enrichment analyses and 
laboratory verification consistently pointed at the same 
small group of gene categories, namely (1)neuroepi-
thelial genes, and in particular the protocadherins; (2) 
fat homoeostasis/body mass genes; (3) olfactory recep-
tors; (4) the cancer/testis antigens; and (5) the UGT1A 
complex.
Protocadherins are major targets of DNA methylation 
in human cells
Emerging evidence suggests that the clustered proto-
cadherin genes may be central to specifying individual 
neural cell identity [47, 48] and they have been shown to 
become heavily methylated during embryonic develop-
ment in mouse [49], suggesting that stable repression of 
non-transcribing copies is a programmed event during 
development. Recent work has shown that DNMT3B is 
important for de novo methylation at these loci and sug-
gested that dysregulated expression may contribute to the 
phenotype in immunodeficiency, chromosome abnor-
malities and facial anomalies (ICF) syndrome [50], where 
DNMT3B is frequently mutated [51], and we found that 
depletion of DNMT3B was accompanied by loss of meth-
ylation at PCDHGA2. The PCDHA and PCDHB loci are 
heterochromatic and show persistent loss of methyla-
tion, as does the 5′ end of the PCDHG locus which is 
polycomb-repressed, but not the 3′ end which shows lit-
tle loss of methylation and has instead chromatin marks 
associated with weak transcription (Additional file 3: Fig. 
S2B). Meehan and co-workers recently showed that long-
term loss of DNA methylation in mouse Dnmt1 −/− ES 
cells led to spreading of polycomb marks (in particular 
H3K27me3): their analyses singled out the Pcdh genes, 
which were heavily methylated in WT but not mutant 
ESC, as also shown by others [52]. Reddington et  al. 
[17] also showed an increase in H3K27me3. A similar 
sequence of events in our human cells would cause an 
increase in H3K27me3 on PCDH genes and potentially 
help block remethylation. The sensitivity of the proto-
cadherin cluster to methylation changes may explain 
why these genes are frequently identified in screens for 
differentially methylated loci in cancer [53]. The lack of 
derepression in our stable fibroblast cells is unsurpris-
ing here since expression of these genes is restricted to 
neurons [54]: they are also, with the exception of part of 
the PCDHG complex, heterochromatic rather than poly-
comb-repressed and may as such be harder to reactivate.
Fat/body mass genes can be repressed by DNA 
methylation and polycomb
Currently, there is much interest in the possibility that 
altered diet, folate status or exposure to environmental 
toxins may lead to stable changes in the human methyl-
ome which particularly affect metabolic processes, as this 
offers an attractive mechanism by which it may be possi-
ble to partly explain the foetal origins of adult disease [55, 
56]. Enrichment analysis in our cells identified the FBM 
genes involved in the common processes of lipid storage 
and body mass homoeostasis, including LEP, GHSR and 
the APOC cluster. These loci are readily demethylated 
on acute DNMT1 depletion and remain demethylated 
in chronically depleted cells where many other loci have 
(See figure on previous page.) 
Fig. 8 Methylation gain is concentrated at poised promoters. a UGT1A locus showing siRNA treatment data (top), shRNA lines (middle) and chroma‑
tin states (bottom); grey, heterochromatin/low signal; green, transcriptionally active (for full key see previous fig). b Median β levels for probes gain‑
ing and losing in shRNA lines (bottom) and median changes in methylation (∆β) versus WT for different chromatin states. c Boxplots of methylation 
values for probes falling within weak and poised promoter chromatin regions in WT or shRNA lines (averaged). d Transcription at the UGT1A3 and 
UGT1A6 genes decreases (relative to WT, set to 1) in all three shRNA lines as methylation (β value) increases, as indicated by HT12 and 450K arrays, 
respectively. e Median methylation (β) across all UGT1A exons decreases in siRNA‑treated cells, but shows gains in all shRNA lines. f Methylation at 
UGT1A2 during the transient KD and recovery experiment shown in Fig. 7h, i; differences are significant between control (Scr) and d4, but not Scr 
versus d36. g Model for methylation changes which occurred over time following chronic (shRNA) depletion of DNMT1: while polycomb‑marked 
regions (purple) resisted remethylation, most regions (“other”, red) regained normal or near‑normal levels, while poised promoters (green) tended to 
become hypermethylated
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recovered methylation. These loci are heavily marked by 
polycomb in normal fibroblasts, rather than being het-
erochromatic, which can potentially explain both their 
resistance to remethylation and their lack of transcrip-
tional depression in the stable lines. In keeping with this, 
inhibition of the polycomb repressor EZH2 which gener-
ates H3K27me3 marks could reactivate these genes, as 
well as the canonical polycomb targets the HOX genes. 
These results suggest that in cells which have both DNA 
methylation and polycomb-mediated repression, both 
layers of repression must be removed to achieve gene 
activation. Interestingly a recent report by Hajkova and 
colleagues showed that reprogramming of germ cells in 
mouse also required both removal of DNA methylation 
and alteration of polycomb marks [57].
Olfactory genes are methylated and largely inert
Olfactory receptors are also involved in specification 
of neural cell identity, where individual receptors are 
expressed in only a small group of cells in the olfac-
tory epithelium [58]. They are largely monoallelically 
expressed, and methylation has been implicated as play-
ing a role in their control [59, 60]. The OR gene fam-
ily is the largest in the genome, with approx. 380 active 
members, many organised into “gene factories” where 
they are flanked by many more pseudogenes and repeats, 
such as the large cluster on chr11 [41]. These regions are 
often transcriptionally inert and heterochromatic, which 
together with the requirement for tissue-specific factors 
may explain their lack of derepression.
Cancer/testis antigen genes are particular targets 
for demethylation and activation
The TSPY and MAGE genes fall into a function-
ally defined group known as the cancer/testis antigen 
(CTA) genes ([61, 62]; http://www.cta.lncc.br/) which 
are expressed during testis development normally, but 
which are aberrantly expressed in some tumours, such 
as melanoma and gonadoblastoma (e.g. TSPY2). This 
latter property makes them of particular interest for 
cancer immunotherapy, and monoclonal antibodies 
against some CTA members have already gained clinical 
approval [63]. CTA genes have been shown previously 
to lose methylation and become derepressed in several 
cancer cell types after treatment with the methyltrans-
ferase inhibitor 5′aza-2-deoxycytidine (Aza) [64–66] 
and in the HCT116 DNMT1 mutant line [66, 67] using 
locus-specific approaches. Our study (1) shows in an 
unbiased genomic screen that CTA genes are the genes 
most affected by loss of maintenance activity, (2) shows 
this for the first time in a normal, differentiated cell 
line and (3) highlights the subset of CTA genes which 
are particularly dependent on maintenance activity to 
keep them repressed. It is noteworthy that the majority 
of these genes are on the X chromosome, which shows 
major fluxes in methylation in our stable lines. The genes 
are largely associated with heterochromatin, rather than 
polycomb repression, and do not respond to EZH2 inhi-
bition, but rather directly to loss of methylation, which 
may reflect some difference in heterochromatin mark-
ing on the X. Strategies to demethylate and turn on these 
genes in tumour cells (e.g. with Aza) to facilitate cancer 
vaccine development may be worthwhile to pursue, given 
that these genes are the most responsive to loss of meth-
ylation in our cell lines.
UGT1A genes and other poised promoters are susceptible 
to hypermethylation
From the enrichment analysis, the UGT1A gene clus-
ter was highlighted in terms of genes gaining methyla-
tion. These genes are known to be highly expressed in 
skin fibroblasts postnatally, and to be repressed in non-
expressing tissues by methylation [68, 69]. The WT cells 
already had substantial levels of methylation but the 
increased methylation in the stable cell lines led to small 
but consistent decreases in transcription on the HT12 
array, though levels were so low these could not be con-
firmed by Taqman qPCR (data not shown). It may be that 
the particular marks associated with a recent inactivation 
of the UGT1A cluster in the fibroblasts during adaptation 
to cell culture led to an increased de novo activity here, 
and in our transient KD experiment we saw the greatest 
gains in methylation at UGT1A4. Consistent with this, 
hypermethylation relative to the WT cells was associated 
with weak and poised promoters genome-wide, and the 
latter showed the greatest tendency to gain methylation 
above normal WT levels in the shRNA-containing lines.
Lack of transcriptional changes in part due to polycomb
It is notable that while there was widespread changes in 
methylation in the KD cell lines, this was not accompa-
nied by large-scale transcriptional derepression, with 
only a few hundred genes showing dysregulation, and 
the fold change in transcription being small. Of the four 
gene classes identified as most affected in terms of meth-
ylation, only one—that containing the TSPY and MAGE 
Page 19 of 21O’Neill et al. Epigenetics & Chromatin  (2018) 11:12 
genes—showed robust transcriptional derepression. A 
lack of global changes in transcription, also reported by 
others [29, 70], is likely due to in part to the absence of 
transcription factors in fibroblasts needed to transcribe 
neural or adipocyte genes at high levels. However, many 
of the regions showing most persistent hypomethylation 
are polycomb-marked and this is likely to be sufficient 
in itself, as it is for example in Drosophila, to main-
tain repression of these genes. However, we could show 
that in the presence of an EZH2 inhibitor, polycomb-
marked loci which lacked DNA methylation, such as 
those involved in fat homoeostasis/body mass regulation, 
became upregulated, along with canonical polycomb tar-
gets such as the HOX genes. Our results therefore indi-
cate both that the polycomb system is sufficient in itself 
to repress and also that polycomb-repressed regions 
appear to be refractive to remethylation, which may be 
due to the action of FBXL10 [71]. It has previously been 
proposed that the two systems work in parallel, with their 
own sets of targets and a degree of mutual exclusivity 
[15–17]: our results would support such a conclusion.
Comparison to other recent work
Two recent studies have also examined the effects of 
DNMT1 mutation on DNA methylation and gene 
transcription in human, albeit in cancer cells [29, 70]. 
Acute depletion of DNMT1 using an siRNA-mediated 
approach found, as we did, regions of low CpG density 
(open sea, etc.) to be most affected, but differed in find-
ing more evidence for cell morphogenesis and phospho-
rylation pathways being affected [70]. This might reflect 
differences between acute and chronic depletion and the 
high levels of cell death during acute depletion. Blattler 
and colleagues [29] also found that relatively few genes 
were dysregulated in DNMT1/3B double KO HCT116 
cells, but some cancer/testis genes (the related GAGE 
genes) were upregulated, along with Krüppel-associated 
box genes, while chaperonins figured prominently among 
down-regulated genes. The latter two gene classes may 
therefore be more dependent on DNMT3B, or the com-
bination of DNMT1 and 3B, for their maintenance; alter-
natively the differences may be due to the experiment 
being carried out in colon cancer cells rather than, as 
here, in non-transformed fibroblasts.
Conclusions
In conclusion, our study sheds new light on the loci 
which are most sensitive to sustained loss of mainte-
nance activity in humans and shows an interplay between 
polycomb and DNA methylation-mediated repression in 
these differentiated cells.
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Additional file 2: Figure S1. Variation between shRNA clonal lines. (A) 
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total variance explained by each component is indicated in brackets. (B) 
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(high).
Additional file 3: Figure S2. Changes in methylation levels by genomic 
element. (A) Protein levels in knockdown lines by western blotting. As a 
control HCT116 colon cancer cells which are WT or have a homozygous 
mutation in DNMT1 (KO) are shown: the DNMT1‑specific top band is 
indicated by the arrowhead at right. (B) Median levels of methylation are 
shown for each genomic element (listed at top). The positions of medians 
are also indicated at right (arrowheads). The differences between WT and 
KD medians were used to plot Fig. 1d. (C) Density distribution of methyla‑
tion at the three main elements involved in gene regulation, shown by 
cell line. Demethylation seems most marked at gene bodies (Genes), 
indicated by increased density of probes at low methylation (β) values.
Additional file 4: Figure S3. Further analysis of enriched genes. (A)Total 
numbers of sites showing significant changes in methylation at different 
false discovery rates (FDR). Some sites showing gain were found in each 
KD cell line alongside the more numerous sites showing loss. (B) Differen‑
tial methylation between WT and all KD lines using the 1000 best‑ranking 
sites as identified by RnBeads (red). The majority of high‑scoring sites 
common to all three lines lost methylation, but approx. one‑third showed 
gain. (C) Methylation changes at neural identity genes on chromosome 
5. Protocadherins in the α and γ families (PCDHA and PCDHG genes) 
have a clustered arrangement, while genes for the β family members are 
arranged individually. Tracks are as in Fig. 3. The position of the C class 
variable exons in the PCDHA and PCDHG clusters are also shown: gain in 
methylation relative to the siRNA‑treated cells can be seen in the boxed 
regions, which includes the PCDHG constant exons, corresponding to 
transcriptionally active chromatin (green). (D) Median β values for gene 
bodies for olfactory receptors identified by DAVID: differences were signifi‑
cant by Mann‑Whitney U (MWU). (E) Median β values for the promoters 
of genes in the histone modifier group identified by enrichment analysis 
in Table 1. No significant differences between WT and KD were found by 
MWU.
Additional file 5: Table S2. Details of the hypomethylated and hyper‑
methylated genes from Figs. 3d and 5a, respectively.
Additional file 6: Table S3. Details of the genes showing transcriptional 
changes in KD cell lines from Fig. 6c.
Additional file 7: Figure S4. Role of DNMT3B in hTERT1604. (A) DNMT3B 
mRNA levels from the HT12 transcription array (3 probes) did not differ 
substantially in DNMT1 shRNA cell lines from WT cells. (B) Successful 
depletion of DNMT3B mRNA using siRNA for 48hr, versus a scrambled 
control (Scr). (C) Methylation levels by pyroassay at the indicated loci: KD, 
knockdown. Methylation levels at 72hr were similar (not shown).
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